Condition
Classic Galactosemia
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Completed4
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03838016Early Phase 1CompletedPrimary
Preventing Speech and Language Disorders in Children With Classic Galactosemia
NCT04902781Phase 2CompletedPrimary
Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia
NCT04117711Phase 1CompletedPrimary
Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia
NCT05418829Phase 3UnknownPrimary
AT-007 in Adult Subjects With Classic Galactosemia (CG)
NCT03580122Phase 2CompletedPrimary
The Effect of Arginine on Classic Galactosemia
Showing all 5 trials